From 2003 to 2022 in Sweden, HCM incidence doubled from 5.0 to 10.0/100,000, prevalence rose from 14.6 to 76.2/100,000, with mortality halved to 4.8%.
The incidence and prevalence of diagnosed hypertrophic cardiomyopathy in Sweden have significantly increased over the past two decades, driven largely by non-obstructive cases, alongside a halving of all-cause mortality.
Absolute Event Rate: 0% vs 0%
Abstract Introduction Hypertrophic cardiomyopathy (HCM) is a myocardial disease with an estimated incidence ranging from 4 to 7 per 100,000 person-years. Imaging-based studies report a prevalence of HCM of about 200 per 100,000 population, in contrast to approximately 7 to 80 per 100,000 population in observational studies. Previous studies have shown an a increase in recorded diagnostic codes for cardiomyopathies until 2006. If this trend continued and specifically affects the incidence and prevalence of HCM up to date remains unclear. Purpose To evaluate the incidence and prevalence of HCM with and without left ventricle outflow tract obstruction, and to describe the trends of these during the years 2003 to 2022. Methods Data from the National Patient Register, including all patients aged 17 years or older diagnosed with HCM in both in-hospital and in out-patient specialised care, during the years 2003-2022 were analysed. Patients were categorised based on a first ever ICD 10-diagnostic code specifying obstructive (I42.1, OHCM) and non-obstructive (I42.2, nonOCHM) HCM. The yearly incidence rate and prevalence per study period year were calculated, adjusted for age and sex. Mortality data were obtained from the National Cause of Death Register, presented adjusted for age and sex. Results A total of 12,288 patients (median age 68.0 17.0–100.0 years, 58% male, 67% nonOHCM) with a first ever HCM diagnosis were included for analysis. NonOHCM patients were significantly younger (64.6 years vs 66.2 years), more frequently male (61.4% vs 49.6% men) compared to OHCM patients. The incidence rate for HCM increased from 5.0 to 10.0 per 100,000 person-years, with 86% attributed to nonOHCM, fig 1. The prevalence increased from 14.6 to 76.2 per 100,000 population, with 82% attributed to nonOHCM, fig 2. The all cause-mortality per study period year decreased from 10,5% to 4,8% in all HCM, from 12.1% to 4.8% in nonOHCM, and from 8.3% to 4.8% in OHCM. Conclusions Over 20 years, the incidence of diagnosed HCM doubled, 86% of which was attributed to nonOHCM. The increase in prevalence was considerable; OHCM almost quadrupled and nonOHCM increased more than six-fold, partially due to an overall halved mortality.
Silverdal et al. (Sat,) reported a other. From 2003 to 2022 in Sweden, HCM incidence doubled from 5.0 to 10.0/100,000, prevalence rose from 14.6 to 76.2/100,000, with mortality halved to 4.8%.